The startup develops epigenetic biomarkers using chromosome conformation signatures to personalize health diagnostics for both animals and humans. Their technology enhances the accuracy of diagnosing and predicting outcomes for mild traumatic brain injuries.
Funding
$2.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current diagnostic methods often fail to capture the complex interplay of genetic, lifestyle, and environmental factors that influence health and wellness. This limitation hinders the development of truly personalized and preventative healthcare strategies for both humans and animals. Existing diagnostic tools may also lack the sensitivity to detect early signs of disease or predict individual responses to interventions like exercise.
Solution
Holos Life Sciences leverages chromosome conformation signatures (CCS) to develop epigenetic biomarkers that provide a more comprehensive view of an individual's health status. Their technology, based on the EpiSwitch™ platform, analyzes the 3D structure of the genome to identify stable, binary biomarkers with predictive and prognostic value. By integrating multi-omic data, Holos aims to create personalized health insights that can be used to improve diagnostics, predict outcomes, and enhance wellness. The company's approach has applications in both human and animal health, including improving the diagnosis and prognosis of mild traumatic brain injury and predicting exercise response.
Target Audience
The primary target audience includes healthcare providers, researchers, and individuals seeking personalized health insights, as well as veterinarians and animal owners looking to optimize animal health and performance.
Features
- Utilizes the EpiSwitch™ platform to identify chromosome conformation signatures (CCS)
- Develops epigenetic biomarkers that integrate genetic, lifestyle, and environmental factors
- Focuses on 3D genomics for predictive and prognostic indicators
- Aims to provide personalized and actionable preventative healthcare
- Applicable to both human and animal health
- Has potential applications in non-disease state problems to enhance health, wellness, and performance